JD Health International Inc. (HKG:6618)
55.95
+2.05 (3.80%)
Aug 13, 2025, 4:08 PM HKT
Paramount Global Revenue
In the year 2024, JD Health International had annual revenue of 58.16B CNY with 8.65% growth. JD Health International had revenue of 29.82B in the half year ending December 31, 2024, with 12.47% growth.
Revenue
58.16B CNY
Revenue Growth
+8.65%
P/S Ratio
2.89
Revenue / Employee
16.32M CNY
Employees
3,564
Market Cap
179.05B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 58.16B | 4.63B | 8.65% |
Dec 31, 2023 | 53.53B | 6.79B | 14.54% |
Dec 31, 2022 | 46.74B | 16.05B | 52.32% |
Dec 31, 2021 | 30.68B | 11.30B | 58.30% |
Dec 31, 2020 | 19.38B | 8.54B | 78.77% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines | 35.81B |
Hansoh Pharmaceutical Group Company | 13.05B |
Innovent Biologics | 10.03B |
Akeso | 2.26B |
Sino Biopharmaceutical | 30.72B |
WuXi Biologics | 19.87B |
CSPC Pharmaceutical Group | 28.99B |
Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |